Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 3, 2014, Pages 471-476

  Kai, Li ^a   Wang, Zuopeng ^a   Yao, Wei ^a   Dong, Kuiran ^a   Xiao, Xianmin ^a  

^a CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Kaposiform hemangioendothelioma; Sirolimus; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; RAPAMYCIN; VINCRISTINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSISTED VENTILATION; BCG VACCINATION; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CUSHINGOID SYNDROME; DISEASE COURSE; FEMALE; HEMANGIOENDOTHELIOMA; HUMAN; INFANT; INTUBATION; KAPOSIFORM HEMANGIOENDOTHELIOMA; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MUSCLE ATROPHY; NERVE COMPRESSION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RELAPSE; REVACCINATION; RISK FACTOR; SCIATIC NERVE INJURY; SYMPTOM; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIBIOTICS, ANTINEOPLASTIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMANGIOENDOTHELIOMA; HUMANS; INFANT; INFANT, NEWBORN; KASABACH-MERRITT SYNDROME; MALE; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; SIROLIMUS; TREATMENT OUTCOME;

EID: 84896713683     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1549-3     Document Type: Article

References (30)

1. Alvarado Y et al (2011) Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Target Oncol 6(2):69-94
2. Castilho R, Squarize C, Gutkind J (2013) Exploiting PI3 K/mTOR signaling to accelerate epithelial wound healing. Oral Dis 19(6):551-558
3. Croteau SE et al (2013) Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 162(1):142-147
4. DeFatta RJ et al (2005) Kaposiform hemangioendothelioma: case report and literature review. Laryngoscope 115(10):1789-1792
5. Deb G (2003) Kaposiform hemangioendothelioma and therapy with interferon-alpha. Med Pediatr Oncol 41(6):593
6. Debelenko LV et al (2005) D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in Kaposiform hemangioendothelioma. Mod Pathol 18(11):1454-1460
7. Dresse MF et al (1991) Successful treatment of Kasabach-Merritt syndrome with prednisone and epsilon-aminocaproic acid. Pediatr Hematol Oncol 8(4):329-334
8. Fahrtash F, McCahon E, Arbuckle S (2010) Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine. J Pediatr Hematol Oncol 32(6):506-510
9. Falger JC et al (2006) Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 10(5):565-569
10. Fasolo A, Sessa C (2011) Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 20(3):381-394
11. Flores MV et al (2010) Visualization of embryonic lymphangiogenesis advances the use of the zebrafish model for research in cancer and lymphatic pathologies. Dev Dyn 239(7):2128-2135
12. Fuchimoto Y et al (2012) Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies. Pediatr Int 54(2):285-287
13. Garcia CD et al (2006) Conversion to sirolimus in pediatric renal transplantation recipients. Transplant Proc 38(6):1901-1903
14. Garcia-Monaco R et al (2012) Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns. J Vasc Interv Radiol 23(3):417-422
15. Haisley-Royster C et al (2002) Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 24(6):459-462
16. Hammill AM et al (2011) Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 57(6):1018-1024
17. Hu B et al (1998) Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J Pediatr Hematol Oncol 20(6):567-569
18. Huber S et al (2007) Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 71(8):771-777
19. Issaka RB et al (2009) Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol 175(4):1410-1420
20. Jiang RS, Hu R (2012) Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery. Int J Clin Oncol 17(5):512-516
21. Kaylani S, Theos AJ, Pressey JG (2013) Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr Dermatol 30(6):e194-e197
22. Kobayashi S et al (2007) Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98(5):726-733
23. Le Huu AR et al (2010) Expression of prox1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angioma. Am J Surg Pathol 34(11):1563-1573
24. Lopez V et al (2009) Successful management of Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using vincristine and ticlopidine. Pediatr Dermatol 26(3):365-366
25. Low IC, Yang RY, Symmans PJ (2013) Microscopic Kaposiform hemangioendothelioma with extensive lymphangiomatosis: an extraordinary example of an unusual entity. Int J Surg Pathol 21(3):297-302
26. Trenor CR (2011) Sirolimus for refractory vascular anomalies. Pediatr Blood Cancer 57(6):904-905
27. Vinayak S, Carlson RW (2013) mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park), 27(1):38-44, 46, 48 passim
28. Wander SA et al (2013) PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat 138(2):369-381
29. Yadav D et al (2011) Neonatal Kasabach-Merritt phenomenon. Indian J Med Paediatr Oncol 32(4):238-241
30. Yasui N et al (2013) Kasabach-Merritt phenomenon: a report of 11 cases from a single institution. J Pediatr Hematol Oncol 35(7):554-558